Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 149,625 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 149,625 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $0.37, for a total value of $55,361.25. Following the completion of the transaction, the insider directly owned 331,414 shares in the company, valued at approximately $122,623.18. This trade represents a 31.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. sold 128,770 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.39, for a total value of $50,220.30.
• On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $68,176.40.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Down 7.4%

Shares of NASDAQ HOWL traded down $0.03 during mid-day trading on Tuesday, hitting $0.36. The company had a trading volume of 580,233 shares, compared to its average volume of 468,701. Werewolf Therapeutics, Inc. has a one year low of $0.36 and a one year high of $2.38. The company has a market capitalization of $17.50 million, a PE ratio of -0.29 and a beta of 0.29. The firm has a 50-day simple moving average of $0.65 and a two-hundred day simple moving average of $0.71.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Regal Investment Advisors LLC boosted its holdings in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the period. Susquehanna International Group LLP boosted its holdings in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter worth approximately $304,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

HOWL has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.